Clinical Trials in Lithuania

• A Study to Evaluate the Efficacy and Safety of Crovalimab versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemog… Ended
  2023-506498-36-00 Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) F. Hoffmann-La Roche AG
• Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed … Ended
  2023-504959-27-00 Phase III Participants with Limited Stage-Small Cell Lung Cancer, who … Merck Sharp & Dohme LLC
• An open study for participants who have been on darolutamide treatment in any other Bayer study Ended
  2022-502084-38-00 Phase III Cancer Bayer Consumer Care AG
• Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended
  2024-514404-13-00 Phase III Atopic Dermatitis Galderma S.A.
• A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed … Ended
  2022-502746-27-00 Phase III Endometrial Cancer AstraZeneca AB
• A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease (VIVID-2) Ended
  2022-502841-91-00 Phase III Crohn’s Disease Eli Lilly & Co.
• Investigation of Radium-223 dichloride (Xofigo), a treatment that gives off radiation that helps kill cancer cells, compared to a treatment … Ended
  2023-505830-89-00 Phase IV metastatic castrate resistant prostate cancer (mCRPC) Bayer AG; Bayer Consumer Care AG
• Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma Ended
  2023-507419-37-00 Phase III Plasma cell myeloma Sanofi-Aventis Recherche & Developpement
• A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended
  2024-518318-25-00 Phase III Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloido… Alnylam Pharmaceuticals Inc.
• Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell… Ended
  2023-503591-25-00 Phase III Non-small cell lung cancer Merck Sharp & Dohme LLC
• Parent and/or Legal Guardian ICF and Adult patient ICF: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study wi… Ended
  2022-501012-34-00 Phase III Pulmonary Arterial Hypertension Actelion Pharmaceuticals Ltd.
• Research study to look at how well the drug Concizumab works in your body if you have haemophilia without inhibitors Ended
  2023-506831-13-00 Phase III haemophilia A (HA) without inhibitors and haemophilia B (HB)… Novo Nordisk A/S
• ELEVATE UC OLE: An Open-Label Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Ended
  2024-515156-21-00 Phase III Ulcerative Colitis Arena Pharmaceuticals Inc.
• HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended
  2022-502478-18-00 Phase II Acute Myeloid Leukemia (AML) Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
• A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or … Ended
  2023-505478-14-00 Phase III Psoriatic Arthritis AbbVie Deutschland GmbH & Co. KG
• Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio… Ended
  2022-502832-37-00 Phase III Acute myeloid leukemia Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
• Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) Ended
  2023-505495-30-00 Phase III Immunoglobulin A Nephropathy (IgAN) Travere Therapeutics Inc.
• An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended
  2023-507906-15-00 Phase III Relapsing multiple sclerosis (RMS) Novartis Pharma AG
• A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or inter… Ended
  2022-501485-22-00 Phase III Myelodysplastic syndrome (MDS) Celgene Corp.
• KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treat… Ended
  2024-513912-89-00 Phase II/III Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosi… Kartos Therapeutics Inc.
• A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Ended
  2023-506994-36-00 Phase III Ulcerative Colitis AbbVie Deutschland GmbH & Co. KG
• LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Ended
  2023-507657-15-00 Phase III Ulcerative Colitis Eli Lilly & Co.
• A randomized phase II study comparing atezolizumab after concurrent chemoradiotherapy with chemoradiotherapy alone in limited disease small-… Ended
  2024-515755-37-00 Phase II Limited disease small-cell lung cancer Norwegian University Of Science And Technolology
• Research study to evaluate the experimental drug ferumoxytol, to see how well it works for children with chronic kidney disease (CKD) and ir… Ended
  2024-516263-92-00 Phase III Iron Deficiency Anemia (IDA) in Pediatric Subjects with Chro… Amag Pharmaceuticals Inc.

Showing 145–168 of 238 trials